Not applicableUnknownNCT01986595What this trial is testingA Pilot Study on ALK Gene Mutations in NeuroblastomaWho this might be right forNeuroblastoma National Taiwan University Hospital 100
Testing effectiveness (Phase 2)Looking for participantsNCT04322890What this trial is testingTreatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationWho this might be right forNon Small Cell Lung CancerEGFR Gene MutationALK Gene Mutation+2 more Hunan Province Tumor Hospital 6,000
Not applicableLooking for participantsNCT05724004What this trial is testingAlectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)Who this might be right forRadiotherapy Side EffectNon-small Cell Lung CancerALK Gene Mutation Karolinska University Hospital 70
Large-scale testing (Phase 3)Looking for participantsNCT05722886What this trial is testingDETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolWho this might be right forHaematological MalignancySolid Tumour Cancer Research UK 825
Testing effectiveness (Phase 2)Ended earlyNCT04644315What this trial is testingA Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsWho this might be right forNeoplasmsColorectal NeoplasmsMelanoma+25 more Hoffmann-La Roche 1
Not applicableLooking for participantsNCT03042221What this trial is testingEarly Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI TherapyWho this might be right forNon-Small Cell Carcinoma of Lung, TNM Stage 4Non-Small Cell Lung CancerEGFR Gene Mutation+3 more University of Colorado, Denver 100
Not applicableStudy completedNCT03944265What this trial is testingGenetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung CancerWho this might be right forActivating ALK Gene Mutation NegativeActivating EGFR Gene Mutation NegativeActivating ROS1 Gene Mutation Negative+5 more Thomas Jefferson University 14
Testing effectiveness (Phase 2)Looking for participantsNCT06378892What this trial is testingEvaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on LorlatinibWho this might be right forNon Small Cell Lung Cancer MetastaticALK Gene Mutation Centro di Riferimento Oncologico - Aviano 45
Early research (Phase 1)Ended earlyNCT04800822What this trial is testingPF-07284892 in Participants With Advanced Solid TumorsWho this might be right forSolid Tumor Pfizer 53
Testing effectiveness (Phase 2)Looking for participantsNCT06620835What this trial is testingTrial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by BrigatinibWho this might be right forNSCLC Groupe Francais De Pneumo-Cancerologie 45
Testing effectiveness (Phase 2)UnknownNCT04989322What this trial is testingPembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLCWho this might be right forNsclcEGFR Activating MutationEGF-R Positive Non-Small Cell Lung Cancer+3 more Dr Joanne CHIU 46
Large-scale testing (Phase 3)Active Not RecruitingNCT02201992What this trial is testingCrizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)Who this might be right forALK Gene RearrangementALK Gene TranslocationALK Positive+5 more ECOG-ACRIN Cancer Research Group 166
Early research (Phase 1)Ended earlyNCT04849273What this trial is testingTPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLCWho this might be right forNon Small Cell Lung CancerNon-Small Cell Lung CancerNSCLC+3 more Turning Point Therapeutics, Inc. 11
Testing effectiveness (Phase 2)WithdrawnNCT03868423What this trial is testingBrigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid CancersWho this might be right forAdvanced Malignant NeoplasmALK Fusion Protein ExpressionALK Gene Amplification+8 more Sameek Roychowdhury
Early research (Phase 1)UnknownNCT04671849What this trial is testingAn Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.Who this might be right forAdvanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Jiangsu Simcere Pharmaceutical Co., Ltd. 243
Not applicableStudy completedNCT02010047What this trial is testingComparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC PatientsWho this might be right forNonsmall Cell Lung Cancer British Columbia Cancer Agency 166
Testing effectiveness (Phase 2)Looking for participantsNCT05266846What this trial is testingPembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALKWho this might be right forALK Gene MutationLung AdenocarcinomaImmunotherapy Hunan Province Tumor Hospital 78
Testing effectiveness (Phase 2)Ended earlyNCT02846792What this trial is testingNivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung CancerWho this might be right forALK Gene TranslocationEGFR Activating MutationRecurrent Non-Small Cell Lung Carcinoma+3 more University of Washington 5
Testing effectiveness (Phase 2)Study completedNCT03049618What this trial is testingRecombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475Who this might be right forALK Gene MutationBRAF Gene MutationEGFR Gene Mutation+9 more University of Southern California 42